Clinical trial
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
NCT00055692 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00055692 |
|---|---|
| Title | Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer |
| Official title | Bevacizumab (RhuMAB-VEGF) In Hepatocellular Cancer For Patients With Unresectable Tumor (Without Invasion Of The Main Portal Vein Or Metastatic Disease) A Phase II Study |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Primary Hepatocellular Carcinoma, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer |
| Intervention type | Biological |
| Interventions | bevacizumab |
| Enrollment | 46 |
| Start date | Feb 1, 2003 |
| Primary completion | Jan 1, 2008 |
| Completion | Dec 1, 2009 |
| First posted | Mar 7, 2003 |
| Last update posted | Feb 29, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: